טוען...
Synergistic growth inhibition by sorafenib and vitamin K2 in human hepatocellular carcinoma cells
OBJECTIVE: Sorafenib is an oral multikinase inhibitor that has been proven effective as a single-agent therapy in hepatocellular carcinoma, and there is a strong rationale for investigating its use in combination with other agents. Vitamin K2 is nearly non-toxic to humans and has been shown to inhib...
שמור ב:
| Main Authors: | , , , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
2012
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3438252/ https://ncbi.nlm.nih.gov/pubmed/23018309 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.6061/clinics/2012(09)18 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|